semaglutide vs tirzepatide weight loss differences vs. for tirzepatide vs semaglutide weight loss

Novo Nordisk announced headline results from STEP UP, a phase IIIb trial investigating subcutaneous semaglutide 7.2 mg for obesity Novo Nordisk announced headline results from STEP UP, a phase IIIb trial in the global STEP programme

Medical supervision required alongside existing diabetes treatments

The familiar approach is understandable, but it has a predictable friction point, especially during transitions off therapy or onto a different medication

New-onset diabetes can mimic Zepbound effects, especially in patients who started with prediabetes or insulin resistance

Role of the cAMP sensor Epac as a determinant of K-ATP channel ATP sensitivity in human pancreatic beta-cells and rat INS-1 cells